Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to $2.1 million.

  • Gossamer Bio's Change in Accured Expenses rose 161.07% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 148.25%. This contributed to the annual value of -$10.7 million for FY2024, which is 36.59% down from last year.
  • Latest data reveals that Gossamer Bio reported Change in Accured Expenses of $2.1 million as of Q3 2025, which was down 80.57% from $11.0 million recorded in Q2 2025.
  • Gossamer Bio's Change in Accured Expenses' 5-year high stood at $11.0 million during Q2 2025, with a 5-year trough of -$9.3 million in Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$940,000 (2024), whereas its average is -$1.0 million.
  • In the last 5 years, Gossamer Bio's Change in Accured Expenses crashed by 510.33% in 2024 and then soared by 267.44% in 2025.
  • Quarterly analysis of 4 years shows Gossamer Bio's Change in Accured Expenses stood at -$6.2 million in 2022, then surged by 45.74% to -$3.4 million in 2023, then spiked by 72.06% to -$940,000 in 2024, then soared by 161.07% to $2.1 million in 2025.
  • Its Change in Accured Expenses stands at $2.1 million for Q3 2025, versus $11.0 million for Q2 2025 and -$5.8 million for Q1 2025.